




Rotigotine

Revised: May 17, 2021.

CASRN: 99755-59-6



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of rotigotine during breastfeeding, but it suppresses serum prolactin and may interfere with breastfeeding. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information in nursing mothers was not found as of the revision date. Rotigotine lowers serum prolactin.[1,2] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

1. Mastrangelo M, Giannini MT, Carducci CL, et al. Safety and efficacy of rotigotine in 7 patients with monoaminergic neurotransmitter deficiency. J Inher Metab Dis 2016;39 (Suppl 1):S228. Abstract. doi:10.1007/s10545-016-9969-2
2. Daniel JS, Govindan JP, Kamath C, et al. Newer dopaminergic agents cause minimal endocrine effects in idiopathic Parkinson's disease. Clin Med Insights Endocrinol Diabetes. 2014;7:13–7. PubMed PMID: 24855402.

Substance Identification

Substance Name

Rotigotine

CAS Registry Number

99755-59-6

Drug Class

Breast Feeding

Lactation

Dopamine Agonists